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Abstract
Background: Differences between gastrointestinal and cardiovascular effects of traditional NSAID or
cyclooxygenase-2 selective inhibitor (coxib) are affected by drug, dose, duration, outcome definition, and
patient gastrointestinal and cardiovascular risk factors. We calculated the absolute risk for each effect.
Methods: We sought studies with large amounts of information to calculate annualised rates for clearly
defined gastrointestinal (complicated upper gastrointestinal perforations, ulcers, or bleeds, but not
symptomatic or endoscopic ulcers) and serious cardiovascular outcomes (antiplatelet trial collaborators
– APTC – outcome of fatal or nonfatal myocardial infarction or stroke, or vascular death).
Results: Meta-analyses and large randomised trials specifically analysing serious gastrointestinal bleeding
or cardiovascular events occurring with five different coxibs had appropriate data. In total there were 439
complicated upper gastrointestinal events in 49,006 patient years of exposure and 948 serious
cardiovascular events in 99,400 patient years of exposure. Complicated gastrointestinal events occurred
less frequently with coxibs than NSAIDs; serious cardiovascular events occurred at approximately equal
rates. For each coxib, the reduction in complicated upper gastrointestinal events was numerically greater
than any increase in APTC events. In the overall comparison, for every 1000 patients treated for a year
with coxib rather than NSAID, there would be eight fewer complicated upper gastrointestinal events, but
one more fatal or nonfatal heart attack or stroke. Three coxib-NSAID comparisons had sufficient numbers
of events for individual comparisons. For every 1000 patients treated for a year with celecoxib rather than
an NSAID there would be 12 fewer upper gastrointestinal complications, and two fewer fatal or nonfatal
heart attacks or strokes. For rofecoxib there would be six fewer upper gastrointestinal complications, but
three more fatal or nonfatal heart attacks or strokes. For lumiracoxib there would be eight fewer upper
gastrointestinal complications, but one more fatal or nonfatal heart attack or stroke.
Conclusion: Calculating annualised event rates for gastrointestinal and cardiovascular harm shows that
while complicated gastrointestinal events occur more frequently with NSAIDs than coxibs, serious
cardiovascular events occur at approximately equal rates. For each coxib, the reduction in complicated
upper gastrointestinal events was numerically greater than any increase in APTC events.
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Background
Chronic pain, defined as pain of at least moderate sever-
ity, and present every day or almost every day for at least
six months, affects one adult in five in Europe [1], and has
a profound negative impact on quality of life [2]. NSAIDs
(traditional non-selective non-steroidal anti-inflamma-
tory drugs) and coxibs (cyclooxygenase-2 selective inhibi-
tors) are effective analgesics and anti-inflammatory drugs,
and an important pharmacological approach to pain
relief, particularly chronic musculoskeletal pain. Other
analgesics are available, but paracetamol in large, valid tri-
als in osteoarthritis is no more effective than placebo [3],
and opioids, alone or in combination with paracetamol,
have high levels of common adverse events [4].
NSAIDs (and aspirin) are associated with upper [5] and
lower [6-8] gastrointestinal harm, acute renal failure
[9,10] and congestive heart failure [11,12]. Coxibs are dif-
ferentiated by lower rates of upper [13-15] and lower [8]
gastrointestinal harm, including endoscopic ulceration
and frank bleeding events, although the only coxib cur-
rently marketed in the US now carries a black box warning
for gastrointestinal complications, as do all prescription
NSAIDs.
All of these drugs (aspirin, NSAIDs, and coxibs) may also
be associated with increased risk of cardiovascular harm.
There appears to be a dose-related effect of aspirin causing
myocardial infarction in a randomised trial of patients
undergoing endarterectomy [16] and in patients with
colorectal polyps [17], and of coxibs in colorectal polyp
trials [18] where the annual event rate with placebo was
less than 0.5%. In dementia patients with an annual risk
of over 2% with placebo, coxibs were not associated with
more thrombotic vascular events than placebo over sev-
eral years of treatment [18]. In arthritis, the annual risk
with placebo is intermediate between these two condi-
tions, at almost 1%. Increased cardiovascular effects for
coxibs compared with placebo but not NSAIDs have been
seen in studies in patients with arthritis [18-20]. Observa-
tional studies indicate that while some cyclooxygenase
inhibitors (selective and non-selective), including aspirin,
have increased risk of cardiovascular adverse events, oth-
ers do not [21].
Serious gastrointestinal or cardiovascular events may be
rare, but they important because they may not be reversi-
ble and can be life-threatening. There are a number of
issues that complicate interpretation of available evidence
and treatment decisions:
1. Demonstrating statistical significance of differences
between treatment groups when events are rare requires
large numbers of patients. The number of events recorded
in clinical trials or observational studies is often small.
Event rates are of the order of 1% a year or less, and trials
frequently shorter than a year.
2. Cardiovascular events are rarely a primary outcome of
trials, and so even randomised trials become, in effect,
high-quality observational studies. Exceptions are the
recent TARGET [22] and MEDAL [23] trials and the ongo-
ing PRECISION study.
3. In arthritis, placebo-controlled trials may be limited to
6–12 weeks, while active controlled comparisons with
NSAID can last for a year or more. The overall cumulative
rate of events will vary with the duration of the trials, as
will the absolute number of events.
4. Typically in RCTs and observational studies people take
coxibs for longer than they take NSAIDs [24], so that there
is greater exposure to coxibs than NSAIDs, even with the
same number of patients in each treatment group. Analy-
sis using crude events may be different from that using
years of exposure.
5. Trials may involve different patient groups with differ-
ent levels of gastrointestinal or cardiovascular risk. For
example, trials have been conducted in patients with oste-
oarthritis, rheumatoid arthritis, and back pain, the obvi-
ous targets for anti-inflammatory analgesics, in whom
extrapolated 10-year risk of an APTC (Antiplatelet Trial
Collaborators [25]) event (fatal or nonfatal heart attack or
stroke, or cardiovascular death) was about 10% [18].
Because inhibition of cyclooxygenase-2 enzyme has been
considered to be helpful in other conditions, coxibs have
also been used in patients with Alzheimer's disease
(extrapolated 10-year risk of an APTC event about 22%
[18]), and following colorectal cancer surgery to prevent
recurrence (extrapolated 10-year risk of an APTC event
about 5% [18]).
6. Some comparisons are with placebo. Others are with
NSAIDs, but some NSAIDs, like naproxen, are theoreti-
cally capable of themselves reducing cardiovascular events
(much like aspirin). Comparisons with naproxen and
non-naproxen NSAIDs have led to much sub-group anal-
ysis, with the attendant problems [26].
7. Individual trials may use different definitions of an
"event" and may report either events as reported by inves-
tigators, or events determined by an independent adjudi-
cation committee. This can make comparisons between
trials, or combining trial results, difficult, because like
may not always be compared with like.
8. Patients in trials may or may not be permitted to use
low dose aspirin, because aspirin, even at low doses, can
cause gastrointestinal problems and confound results. TheBMC Musculoskeletal Disorders 2007, 8:73 http://www.biomedcentral.com/1471-2474/8/73
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exclusion of patients using aspirin may lead to selection of
patients at lower cardiovascular risk than people in the
community with arthritis or chronic pain who would be
candidates for treatment with NSAID or coxib.
9. Clinical trials of coxibs designed to demonstrate gas-
trointestinal safety, have used doses of coxibs higher than
the maximum licensed daily dose [13-15] for arthritis.
Comparator NSAIDs have been used at the maximum
daily dose. For all drugs adverse events are likely to be
dose related, with higher event rates at higher doses.
Our aim was to use evidence from meta-analyses of clini-
cal trials and cohort studies regarding gastrointestinal
bleeding and APTC events to determine absolute annual-
ised event rates for coxibs and NSAIDs, in order to clarify
comparisons between them, and facilitate treatment
choices.
Methods
We looked for information on complicated gastrointesti-
nal or serious cardiovascular outcomes in randomised
controlled trials and meta-analyses of randomised trials of
coxibs and NSAIDs, and in observational studies. The
main gastrointestinal outcome of interest was adjudicated
report of serious or complicated upper gastrointestinal
perforations, ulcers, or bleeds, but not including sympto-
matic ulcers or ulcers detected endoscopically. Typically in
randomised trials or meta-analyses of randomised trials
this would involve presentation with haematemesis or
melaena, perforation or obstruction, reduction in haemo-
globin of 20 g/L or more, and to have ulcer or erosion in
oesophagus, stomach, or duodenum. The main cardiovas-
cular outcome of interest was the APTC outcome of fatal
or nonfatal myocardial infarction or stroke, or vascular
death. Other outcomes, especially myocardial infarction
and stroke, were tabulated separately, together with all-
cause mortality and cardiovascular mortality. Where avail-
able, adjudicated outcomes were preferred. It was antici-
pated that less well documented outcomes would be
available in cohort studies than in randomised trials,
though in practice cohort studies were not used in any
analysis.
We searched PubMed (to November 2006), using individ-
ual drug names and relevant text words and indexing
terms for drugs, outcomes, and study designs. We also
searched bibliographies and contacted experts and com-
panies for any additional information about available
studies.
For the purposes of this analysis, information was
required from patients predominantly with chronic pain
(osteoarthritis, rheumatoid arthritis, back pain, ankylos-
ing spondylitis), in studies typically of duration longer
than six weeks, with coxib, NSAID or placebo treatment
groups. Randomised trials (alone or in meta-analyses)
needed to be double blind, and have high quality scores.
Observational studies needed to be large and comprehen-
sive.
The information required included the description and
number of events, the number of patients studied, dose of
drug, and the mean duration of exposure per patient, or
total patient years of exposure, or data to make those cal-
culations. Information was extracted by RAM and checked
by SD.
For each coxib and NSAID comparison we calculated the
annualised rate for each outcome. This was done by divid-
ing the actual number of events observed by the number
of person years of observation for each individual treat-
ment arm, as provided in a report, and expressing the
result as the number of events per 100 or per 1000 person
years. Both are used because while the former is equiva-
lent to a percentage rate per annum, it frequently results
in fractions that are less easily understood for description
of risk. For each coxib we calculated the difference
between NSAIDs and coxibs in the number of events for
1000 patients, and expressed the result numerically, as a
frequency, and in words. An assumption of constant risk
over time is justified by linear risks for gastrointestinal
[13,15] and cardiovascular [27] events. Where informa-
tion was available in several studies (for instance in both
a definitive randomised trial and a meta-analysis), we
chose that with the largest number of events, or combined
them, as appropriate.
Results
Additional files contain information, including definition
of outcomes, on major studies (randomised trials, meta-
analyses of randomised trials, and observational studies)
that were examined closely for information on annual
gastrointestinal or cardiovascular event rates, or informa-
tion to calculate annualised event rates [see Additional
files 1 and 2]. Some studies contained information from
the same, or some of the same trials, and our strategy was
to use only the largest or most recent of them. Absolute
risk data were available only from RCTs and meta-analy-
ses of RCTs, and a few cohort studies; the large number of
case-control studies did not have absolute risk rates so
could not be used.
For complicated gastrointestinal events we chose to use
data only from meta-analyses of randomised trials for
celecoxib [28], etoricoxib [29], and valdecoxib [30], for
rofecoxib we combined a meta-analysis [31] with a large
randomised trial [13], and for lumiracoxib we chose a
large randomised trial [15]. These outcomes were all adju-
dicated, apart from those for celecoxib [28]. All of theseBMC Musculoskeletal Disorders 2007, 8:73 http://www.biomedcentral.com/1471-2474/8/73
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sources tested placebo, NSAIDs, and coxibs without resort
to gastroprotective agents like histamine antagonists or
proton pump inhibitors. By contrast, MEDAL [23]
ensured that patients with at least one gastrointestinal risk
factor received gastroprotection with a proton pump
inhibitor; gastrointestinal events from this trial are con-
sidered separately.
For cardiovascular events we chose meta-analyses of ran-
domised trials for celecoxib [19], lumiracoxib [20],
rofecoxib [32], and valdecoxib [33], and for etoricoxib we
combined a large randomised trial [23] with data from a
meta-analysis of previous trials [34]. All outcomes were
adjudicated. Low dose aspirin was not used in many trials,
but was about 20% in CLASS, 22% in TARGET, and 35%
in MEDAL, which formed a large part of the data set to be
used. Because low dose aspirin use was a potential con-
founder, and because myocardial infarction was the major
cardiovascular event, we performed an analysis according
to use or non-use of low dose aspirin, both by events
based on number of patients and by patient years of expo-
sure, and compared both with all NSAIDs and non-
naproxen NSAIDs [see Additional file 3]. These multiple
comparisons failed to show any large difference in event
rates between coxibs and NSAIDs according to low dose
aspirin use, using more data but with a similar result to
other meta-analyses [18]. We therefore used data for all
patients.
For each coxib, information on complicated gastrointesti-
nal and serious cardiovascular adverse events were well
defined. For each coxib analyses of gastrointestinal and
cardiovascular adverse events involved largely the same
trials, and predominantly concerned patients with oste-
oarthritis and rheumatoid arthritis.
Table 1 and Figure 1 show the annualised rates of compli-
cated upper gastrointestinal events (usually defined as
complicated perforations, ulcers, or bleeds) for placebo,
individual coxibs, and NSAIDs aggregated together. The
total number of events was small with placebo (4 events
in 550 patient years, Table 1), larger with coxibs (158
events in 28,000 patient years), and largest with NSAIDs
(277 events in 20,400 patient years). Annualised rates
were numerically higher for NSAIDs than coxibs (Table 1,
Figure 1). It was not possible to analyse individual
NSAIDs separately, or different doses of coxibs or NSAIDs,
due to small numbers of events. Patient characteristics
and baseline risks of these studies were similar. Combin-
ing all coxib studies there were, in total, 439 complicated
upper gastrointestinal events in 49,000 patient years of
exposure, giving an overall rate of one per 112 patients per
year of exposure.
Two cohort studies [see Additional file 1] reported infor-
mation allowing calculation of annualized event rates of
hospital admission with upper gastrointestinal bleed. In
one [35] the annualised event rate was 0.4% for celecoxib
(8,800 patient years), 0.7% for rofecoxib (5,900 patient
years), and 1.3% for NSAIDs (1,400 patient years). The
other, in the UK [36], had lower rates of 0.25% for coxibs
(1,600 patient years) and 0.46% for NSAIDs (based on
635,000 patient years, but over decades). In general these
cohort studies are in agreement with the results of meta-
analyses of randomised trials (Table 1). The several case-
control studies had no relevant information for annual-
ised rates.
Table 2 and Figure 2 show the annualised rates of cardio-
vascular events (usually defined as the APTC outcome of
fatal or nonfatal heart attack or stroke, or vascular death;
"APTC events") for placebo, individual coxibs, and
NSAIDs aggregated together. The total number of events
was moderate with placebo (52 events in 3,400 patient
years), larger with NSAIDs (395 events in 44,200 patient
years), and largest with coxibs (501 events in 51,800
Table 1: Summary of available best evidence on serious upper gastrointestinal complications
Treatment Best evidence Patient years of exposure Number of events PUB(% per year)
Placebo Meta-analysis of rofecoxib trials [31] 112 3 2.68
Placebo Meta-analysis of celecoxib trials [28] 441 1 0.23
Celecoxib Meta-analysis of celecoxib trials [28] 7943 74 0.93
Etoricoxib Meta-analysis of etoricoxib trials [29] 4007 19 0.47
Lumiracoxib RCT [15] 6368 29 0.46
Rofecoxib Meta-analysis of rofecoxib trials [31,13] 8524 28 0.33
Valdecoxib Meta-analysis of valdecoxib trials [30] 1183 8 0.68
NSAID Meta-analysis of celecoxib trials [28] 5258 110 2.09
NSAID Meta-analysis of etoricoxib trials [29] 2230 23 1.03
NSAID RCT with lumiracoxib [15] 6845 83 1.21
NSAID Meta-analysis of rofecoxib trials [31,13] 5532 50 0.90
NSAID Meta-analysis of valdecoxib trials [30] 563 11 1.95
PUB – perforations, ulcers, bleeds; RCT – randomised controlled trialBMC Musculoskeletal Disorders 2007, 8:73 http://www.biomedcentral.com/1471-2474/8/73
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patient years). Annualised rates were similar for coxibs
and NSAIDs (Table 2, Figure 2). Combining all coxib
studies there were, in total, 948 cardiovascular events in
99,400 patient years of exposure, giving an overall rate of
one per 105 patients per year of exposure.
Two cohort studies [see Additional file 2] reported infor-
mation allowing calculation of annualised rates for com-
parison with meta-analyses of randomised trials. One [37]
used APTC events and reported rates between 1.2% and
1.4% for controls, NSAIDs, and coxibs, with between
5,600 and 240,000 patient years of observation for each
drug. The other reported hospital admission for myocar-
dial infarction [38] with reported rates of 1.2% for
celecoxib (7,000 patient years), rofecoxib (4,800 patient
years), and NSAIDs (12,600 patient years). Again, these
cohort studies are in agreement with the results of meta-
analyses of randomised trials (Table 2).
Gastrointestinal versus cardiovascular outcomes for 
individual coxib-NSAID comparisons
The calculations for all coxibs combined versus all
NSAIDs, and for individual coxib versus all NSAIDs
within direct comparisons, using the best evidence availa-
ble from meta-analyses of randomised trials, are shown in
Table 3, and Figure 3 where similar molecular structures
are adjacent. Table 3 and Figure 3 do not consider that in
all cases there was a statistically significant reduction in
complicated gastrointestinal events, but no significant dif-
ference in cardiovascular events. The calculations are
based solely on the absolute event rates for the two differ-
ent events, gastrointestinal and cardiovascular. Calcula-
tions for all coxibs vs all NSAIDs use average annual event
rates.
Table 3 gives not only the event rates, but the absolute
annual frequency of each of these events occurring with
NSAID or coxib. Although different reports were used to
calculate gastrointestinal and cardiovascular event rates,
these reports used essentially the same trials or patient
populations for each coxib, so that a direct comparison
between the two different events was justified. The differ-
ence in absolute event rates expressed as a frequency is
equivalent to a number needed to treat to prevent an
event (if a positive number), or a number needed to harm
(if a negative number).
The overall comparison shows that for every 1000
patients treated for a year with any coxib rather than any
Table 2: Summary of available best evidence on APTC events
Treatment Best evidence source [reference] Patient years of exposure Number of events APTC(% per year)
Placebo Meta-analysis of celecoxib trials [19] 585 8 1.40
Placebo Meta-analysis of etoricoxib trials [34] 335 4 1.20
Placebo Meta-analysis of lumiracoxib trials [20] 614 6 1.00
Placebo Meta-analysis of rofecoxib trials [32] 1678 32 1.90
Placebo Meta-analysis of valdecoxib trials [33] 161 2 1.25
Celecoxib Meta-analysis of celecoxib trials [19] 5651 57 1.10
Etoricoxib Meta-analysis of etoricoxib trials [23, 34] 30404 277 0.91
Lumiracoxib Meta-analysis of lumiracoxib trials [20] 7859 72 0.92
Rofecoxib Meta-analysis of rofecoxib trials [32] 6556 78 1.19
Valdecoxib Meta-analysis of valdecoxib trials [33] 1340 17 1.27
NSAID Meta-analysis of celecoxib trials [19] 4386 54 1.20
NSAID Meta-analysis of etoricoxib trials [23, 34] 27644 232 0.80
NSAID Meta-analysis of lumiracoxib trials [20] 6805 55 0.82
NSAID Meta-analysis of rofecoxib trials [32] 4726 41 0.87
NSAID Meta-analysis of valdecoxib trials [33] 656 13 1.97
APTC – Antiplatelet Triallists Collaboration outcome of fatal and nonfatal heart attack or stroke, and cardiovascular death
Incidence of complicated upper gastrointestinal complica- tions in individual RCTs and meta-analyses Figure 1
Incidence of complicated upper gastrointestinal complica-
tions in individual RCTs and meta-analyses. The size of the 
symbol is proportional to patient numbers (inset scale)
0
1
2
3
4
5
6
7
8
0123
Annual risk (%) of PUB
0
10000
20000
30000
NSAID
Valdecoxib
Lumiracoxib
Rofecoxib
Celecoxib
Placebo
EtoricoxibBMC Musculoskeletal Disorders 2007, 8:73 http://www.biomedcentral.com/1471-2474/8/73
Page 6 of 11
(page number not for citation purposes)
NSAID there would be eight fewer upper gastrointestinal
complications, but one more fatal or nonfatal heart attack
or stroke. However, within the different coxib-NSAID
comparisons, there are different results:
For celecoxib, for every 1000 patients treated for a year
with celecoxib rather than an NSAID there would be 12
fewer upper gastrointestinal complications, and two fewer
fatal or nonfatal heart attacks or strokes.
For valdecoxib, for every 1000 patients treated for a year
with coxib rather than an NSAID there would be 13 fewer
upper gastrointestinal complications, and seven fewer
fatal or nonfatal heart attacks or strokes.
For rofecoxib, for every 1000 patients treated for a year
with coxib rather than an NSAID there would be six fewer
upper gastrointestinal complications, but three more fatal
or nonfatal heart attacks or strokes.
For etoricoxib, for every 1000 patients treated for a year
with coxib rather than an NSAID there would be six fewer
upper gastrointestinal complications, but one more fatal
or nonfatal heart attack or stroke.
For lumiracoxib, for every 1000 patients treated for a year
with coxib rather than an NSAID there would be eight
fewer upper gastrointestinal complications, but one more
fatal or nonfatal heart attack or stroke.
The large MEDAL programme of 34,700 patients over
51,000 patient years of observation compared etoricoxib
(plus low dose aspirin or proton pump inhibitor where
indicated) with diclofenac (plus low dose aspirin or pro-
ton pump inhibitor where indicated)[23,39]. The APTC
event rate was about 0.85% in both groups, and is similar
in magnitude to other results for coxibs and NSAIDs
(Table 2). The confirmed complicated upper gastrointesti-
nal event rate was about 0.3% per year in both groups,
and was substantially lower than other results for NSAIDs
(0.9 to 2.1% per year, Table 1), and, indeed some results
for coxibs (0.3 to 0.9% per year, Tables 1).
Discussion
There are many limitations with trying to analyse the bal-
ance of gastrointestinal and cardiovascular risks for coxibs
and NSAIDs.
First among them is an assumption, unstated but implicit,
that these are the only choices for treating pain. They are
not. Other strategies exist that have more or less evidence
for benefit and harm, and encompass both conventional
and unconventional therapies. The case of coxib trials is,
however, unusual in the large number of patients
involved in randomised trials. It has been pointed out that
around 200 events may be necessary to give credibility to
a result [40]. The number of patients involved in trials to
gather a sufficient number of events is likely to be large in
the case of rare but serious adverse events; in the tens of
thousands for small differences between events occurring
at 1% or so [41]. For most therapies we have insufficient
information to exclude the possibility that rare but serious
adverse events are present (a case of absence of evidence
not equating to evidence of absence), so cannot properly
evaluate the balance of benefits and risks. That should not
prevent our trying to look at methods in an area not well
explored, and which has been explored mainly using rela-
tive risks [18] rather than absolute event rates. In this
regard it is worth noting that it has been pointed out that
"All policy decision should be based on absolute measures of
risk: relative risk is strictly for researchers only" [42], so that
using an absolute risk approach would seem to be sensi-
ble. It still needs to be emphasised, though, that trying to
evaluate the risks and benefits of two therapies does not
deny the appropriateness of others for some patients.
Secondly, it is a common experience that particular
patients do particularly well on particular medicines;
while medicines may be equally efficacious on average,
individual responses to the medicine can be dramatically
different [43-45]. Our approach here used only average
data from trials, and the experience of any individual is
likely to be different, and presently not calculable.
Thirdly, this analysis is limited to only two harmful out-
comes, those of serious gastrointestinal or cardiovascular
harm. There are others (congestive heart failure, renal
impairment, anaemia) that might be included in such an
analysis, as meta-analysis of clinical trial reports for
adverse events has shown [28]. Moreover, gastrointestinal
and cardiovascular events need not be equivalent; for each
there is a spectrum of severity, which includes death.
Incidence of serious cardiovascular events in individual RCTs  and meta-analyses The size of the symbol is proportional to  patient numbers (inset scale) Figure 2
Incidence of serious cardiovascular events in individual RCTs 
and meta-analyses The size of the symbol is proportional to 
patient numbers (inset scale).
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Fourthly, while reduction in a harmful outcome is benefi-
cial, the analysis does not consider other benefits of ther-
apy, such as pain relief, functioning, and quality of life.
Fifthly, there is danger that rare adverse events are cap-
tured only in small numbers, with random chance pro-
ducing false results. Ideally substantial numbers of events
should be available [24,46,47]. Information for val-
decoxib was inadequate, with only eight gastrointestinal
and 17 cardiovascular events with valdecoxib (Tables 1
and 2), and similarly small numbers for NSAID compara-
tors. For etoricoxib, 19 and 242 events respectively with
etoricoxib might also be regarded as inadequate for gas-
trointestinal outcomes. Data from the MEDAL program
[39] differed because of the use of proton pump inhibi-
tors, the only trial to do so, and was not used. For the
other coxibs, there was a reasonable, but not overwhelm-
ing, number of events for both coxib and NSAID compa-
rators, making comparison smore robust.
Table 3: Summary of calculations fort individual coxibs, and all coxibs combined
Annual event 
rate per 100
Annual event 
rate per 1000
Absolute risk 
frequency per year
Annual event 
rate per 100
Annual event 
rate per 1000
Absolute risk 
frequency per year
All coxib vs All NSAID Lumiracoxib vs NSAID
PUB PUB
NSAID 1.36 13.6 74 NSAID 1.21 12.1 83
All coxib 0.56 5.6 179 Lumiracoxib 0.46 4.6 217
Difference 8.0 125 Difference 7.5 133
APTC APTC
NSAID 0.89 8.9 112 NSAID 0.82 8.2 122
All coxib 0.97 9.7 103 Lumiracoxib 0.92 9.2 109
Difference -0.8 -1250 Difference -1.0 -1000
Celecoxib vs NSAID Valdecoxib vs NSAID
PUB PUB
NSAID 2.09 20.9 48 NSAID 1.95 19.5 51
Celecoxib 0.93 9.3 108 Valdecoxib 0.68 6.8 147
Difference 11.6 86 Difference 12.7 79
APTC APTC
NSAID 1.20 12.0 83 NSAID 1.97 19.7 51
Celecoxib 1.00 10 100 Valdecoxib 1.27 12.7 79
Difference 2.0 500 Difference 7.0 143
Rofecoxib vs NSAID Etoricoxib vs NSAID
PUB PUB
NSAID 0.90 9.0 111 NSAID 1.03 10.3 97
Rofecoxib 0.33 3.3 303 Etoricoxib 0.47 4.7 213
Difference 5.7 175 Difference 5.6 179
APTC APTC
NSAID 0.87 8.7 115 NSAID 0.80 8.0 125
Rofecoxib 1.19 11.9 84 Etoricoxib 0.91 9.1 110
Difference -3.2 -313 Difference -1.1 -909
PUB – perforations, ulcers, bleeds; APTC – Antiplatelet Triallists Collaboration outcome of fatal and nonfatal heart attack or stroke, and 
cardiovascular death. In these calculations, the annualised event rates have been converted for simplicity to event rates per 1000 patients, and 
absolute event frequency per year calculated from that. Differences between NSAID and coxibs were calculated, and the absolute risk difference 
frequency calculated. This is equivalent to a number needed to prevent one event if positive, and number needed to harm if negative, for one year 
of treatment of coxib rather than an NSAIDBMC Musculoskeletal Disorders 2007, 8:73 http://www.biomedcentral.com/1471-2474/8/73
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Sixthly, it is likely that different drugs have different levels
of cardiovascular risk, irrespective of pharmacological
classification. The best evidence comes from an analysis of
3.5 million patients in case-control studies, showing dif-
ferences within NSAID and coxib classes [21]. Low num-
bers of events made it impracticable to analyse NSAID
comparators individually in this study, but comparing a
particular coxib with a mix of NSAIDs may give only a par-
tial picture. In addition, either or both risks may be dose-
related and there has been a tendency to use higher than
licensed doses in some randomised trials.
This analysis differs from at least one previous attempt to
assess the balance of gastrointestinal and cardiovascular
risks of NSAIDs and coxibs [48], which was qualitative in
nature. We have attempted to remove the effects of differ-
ent exposures by using the number of events per 100 or
per 1000 patient years as a standard, with annualised rates
justified by the observation of constant gastrointestinal
and cardiovascular risk in large randomised studies
[13,15,27]. The level of gastrointestinal or cardiovascular
risk was the same within each comparison, because infor-
mation was taken from meta-analyses of randomised tri-
als conducted on similar patients; this is important,
because the suggestion is that gastrointestinal differences
between coxibs and NSAIDs are greater at higher risk [49],
while significant cardiovascular differences may occur
mainly at lower cardiovascular risk [21,50].
Over and above these problems comes that of comparing
like with like, the same drug and dose, for the same dura-
tion, in similar patients with similar risk factors. The clear-
est way of doing that is to compare, for each coxib,
information for both outcomes derived from meta-analy-
sis of the largest body of data from randomised trials.
Measuring both outcomes in the same population, with
the same drug, dose range, and duration should ensure
the best comparison. Most observational studies have had
a case-control design, with no data on absolute event
rates, limiting their utility for this purpose. The few with
cohort designs had generally similar event rates and con-
clusions as the meta-analyses of randomised trials, and we
used them only to confirm the trial data, not for actual cal-
culations. We were not able to compare gastrointestinal
with cardiovascular event rates at particular drug doses,
because this information was not generally available.
For each coxib, there was a statistically significant reduc-
tion in the number of complicated upper gastrointestinal
events compared with NSAID. The use of complicated
events, rather than all adjudicated perforations, ulcers, or
bleeds, excludes symptomatic ulcers and includes only the
most serious events. This is a conservative approach, and
reduces the number of events substantially. Including less
complicated gastrointestinal events would increase the
balance of gastrointestinal over cardiovascular risk.
For each coxib, no significant difference was found
between coxib and NSAID for APTC events, with either
small reductions for celecoxib and valdecoxib, or small
increases for rofecoxib and etoricoxib. This reflects the
overall results for coxibs and NSAIDs, but not between
coxibs and particular NSAIDs [21].
For each coxib, the reduction in complicated upper gas-
trointestinal events was numerically greater than any
increase in APTC events. There appeared to be a difference
between individual coxibs, reflecting what is seen in
observational studies [21]. The large MEDAL programme
[23,39] was different from other trials, in that it compared
NSAID plus proton pump inhibitor when required with
coxib plus plus proton pump inhibitor when required,
making it more pragmatic than experimental. The impor-
tant result was finding very low rates of complicated upper
gastrointestinal adverse events, indicating the potential
efficacy of either strategy if implemented. Implementa-
tion is the problem, though, because the evidence is that
most patients with gastrointestinal risk factors do not
Event rates for serious gastrointestinal and cardiovascular  events for each coxib, and for all coxibs combined, for 1000  patients treated for one year with each drug Figure 3
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receive protective strategies [51], and that perhaps half of
patients receiving a proton pump inhibitor with an
NSAID do not take it [52].
The question then is whether complicated upper gastroin-
testinal and APTC events are similar or different in sever-
ity. Frank upper gastrointestinal bleeding or perforation,
for any cause, carries a 5%-12% risk of death, although it
may be higher in an emergency, and possibly if NSAID is
also involved [53-55]. A recent case series of surgery for
peptic ulcers showed that half the patients were regular
NSAID users, and for urgent or emergency surgery for
bleeding or perforation, 10/35 patients (29%) died [56].
In APTC events there was separate documentation of car-
diovascular mortality in three studies [19,22,33], where
mortality was about 29%-34% (3 deaths in 10 APTC
events with placebo; 38/133 with coxib; 40/117 with
NSAID). In terms of mortality, the contrasting harms
seem to be similar. Subjectively, of course, heart attack or
stroke may seem to be more serious than gastrointestinal
bleeding, but there is little objective evidence that this is
the case.
Conclusion
Where there is a sufficiency of information, absolute event
rates can be used to compare benefit and harm of rare
events. Using meta-analyses of randomised trials of
patients with arthritis or chronic pain, and calculating
annualised event rates for major gastrointestinal and car-
diovascular harm, shows that while major cardiovascular
events occur at approximately equal rates with NSAIDs
and coxibs, major gastrointestinal events occur more fre-
quently with NSAIDs than coxibs. For each coxib, the
reduction in complicated upper gastrointestinal events
was numerically greater than any increase in APTC events.
Good quality observational studies are in remarkably
good agreement with results from randomised trials.
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